伊立替康治疗晚期或复发性子宫内膜癌的II期试验及其与生物标志物分析的相关性
这项II期试验评估了伊立替康(CPT-11)单药治疗晚期或复发性子宫内膜癌的抗肿瘤活性与毒性。22例可测量病灶患者接受CPT-11 100 mg/m2静脉输注(第1、8、15天,4周一周期)。客观缓解率为36.4%,临床获益率77.3%,中位无进展生存期4.4个月,中位总生存期18.4个月,不良事件可控,未发现疗效生物标志物预测因子。
要点
- 伊立替康单药治疗晚期或复发性子宫内膜癌的客观缓解率为36.4%,临床获益率为77.3%。
- 中位无进展生存期4.4个月,中位总生存期18.4个月。
- 不良事件包括4级血液学毒性(中性粒细胞减少和血小板减少)及2或3级非血液学毒性(腹泻),均可控。
核心结论
- 伊立替康作为单药对晚期或复发性子宫内膜癌具有抗肿瘤活性,且不良事件可控。
研究设计与样本
- II期临床试验, enrolled 22例晚期或复发性子宫内膜癌患者(子宫内膜样癌11例,浆液性癌11例),均具有可测量病灶且接受过2种预处理方案。
主要发现
- 客观缓解率为36.4%(完全缓解1例,部分缓解7例)。
- 临床获益率(包括疾病稳定)为77.3%。
- 中位无进展生存期为4.4个月,中位总生存期为18.4个月。
- 中位无治疗间期(TFI)为7.5个月,中位每例患者接受4个周期。
- 观察到4级血液学毒性(中性粒细胞减少和血小板减少)及2或3级非血液学毒性(腹泻),所有不良事件均可控。
关键数值与推荐
- 伊立替康(CPT-11)100 mg/m2静脉输注90分钟,在第1、8、15天给药,4周为一周期,目标在≤2个周期内见效。
- 抗肿瘤效果按RECIST 1.1版评估,不良事件按NCI-CTC AE 3.0版评估。
- 未观察到疗效生物标志物预测因子。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chemotherapy for advanced or recurrent endometrial cancer requires further development. Irinotecan hydrochloride (CPT-11) suppresses tumor growth in several endometrial cancer strains. The present study evaluated the anti-tumor activity and toxicity of CPT-11 in patients with advanced or recurrent endometrial cancer. METHODS: Enrolled patients had advanced endometrial cancer with measurable lesions and received 2 pretreatment regimens. A 90-minute intravenous infusion of CPT-11 (100 mg/m2) was given on days 1, 8, and 15 of a 4-week cycle, aiming for an effect with ≤2 cycles. Treatment was continued until the primary disease worsened or severe toxicity occurred. The primary endpoint was response rate, and the secondary endpoints were progression-free survival, overall survival, and adverse events. Antitumor effect and adverse events were evaluated according to RECIST version 1.1 and NCI-CTC AE version 3.0, respectively. RESULTS: Twenty-two patients were registered (11 endometrioid carcinomas and 11 serous carcinomas). The median duration of the treatment-free interval (TFI) was 7.5 months, and the median number of administered cycles per patient was 4. Response rate was 36.4% (complete response: 1 patient, partial response: 7 patients). Clinical benefit rate, including stable disease, was 77.3%. Median progression-free and overall survival was 4.4 and 18.4 months, respectively. Observed adverse events included grade 4 hematotoxicity (neutropenia and thrombocytopenia), and grade 2 or 3 non-hematotoxicity (diarrhea). All adverse events were manageable. Biomarker predictors of therapeutic effectiveness were not observed. CONCLUSION: As a single agent, CPT-11 has anti-tumor activity for advanced or recurrent endometrial cancer and has manageable adverse events.
引用
- Nishio S, Shimokawa M, Tasaki K, et al. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis. Gynecol Oncol. 2018. PMID: 30037491. doi:10.1016/j.ygyno.2018.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。